Recent trials

Trials recently included in TrialResults-center.org RSS


Checkmate-141, 2016
NCT02105636
nivolumab vs standard treatment
in Head and neck cancer
31/07/2017 00:00:00

immune checkpoint inhibition for Head and neck cancer in all type of patients

KEYNOTE-040,
NCT02252042
pembrolizumab vs standard treatment
in Head and neck cancer
30/07/2017 00:00:00

immune checkpoint inhibition for Head and neck cancer in all type of patients

CANTOS, 2017
NCT01327846
canakinumab vs placebo
in post acute coronary syndromes
01/07/2017 00:00:00

anti inflammatory drugs for post acute coronary syndromes in all type of patients

anti inflammatory drugs for post myocardial infarction in all type of patients

REVEAL HPS-3 TIMI-55, 2017
NCT01252953
anacetrapib vs placebo
in cardiovascular prevention
01/07/2017 00:00:00

CEPT inhibition for cardiovascular prevention in all type of patients

HDL increasing drugs for cardiovascular prevention in all type of patients

CANTOS, 2017
NCT01327846
canakinumab vs placebo
in post myocardial infarction
01/07/2017 00:00:00

anti inflammatory drugs for post acute coronary syndromes in all type of patients

anti inflammatory drugs for post myocardial infarction in all type of patients

Hyams,
NCT00454805
cediranib + fulvestrant vs fulvestrant
in advanced breast cancer (metastatic)
19/05/2017 00:00:00

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

De Jong, enzastaurin + fulvestrant vs Fulvestrant
in advanced breast cancer (metastatic)
19/05/2017 00:00:00

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

LEA, bevacizumab + endocrine therapy vs endocrine therapy
in advanced breast cancer (metastatic)
19/05/2017 00:00:00

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

angiogenesis inhibitors for advanced breast cancer (metastatic) in first line therapy

Dickler (CALGB 40503°, 2015Letrozole plus bevacizumab vs letrozole
in advanced breast cancer (metastatic)
19/05/2017 00:00:00

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

Aphinity,
NCT01358877
pertuzumab vs placebo
in early breast cancer
05/03/2017 00:00:00

HER2 inhibitors for early breast cancer in HER2 positive patients

KEYNOTE-045,
NCT02256436
pembrolizumab vs investigator’s choice of chemotherapy
in advanced urothelial carcinoma
18/02/2017 00:00:00

immune checkpoint inhibition for advanced urothelial carcinoma in all type of patients

EUCLID, 2016
NCT01732822
ticagrelor vs clopidogrel
in peripheral vascular diseases
14/11/2016 00:00:00

antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication

antiplatelets drug for peripheral vascular diseases in all type of patient

EUCLID, 2016
NCT01732822
ticagrelor vs clopidogrel
in cardiovascular prevention
14/11/2016 00:00:00

antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication

antiplatelets drug for peripheral vascular diseases in all type of patient

AURA 3,
NCT02151981
Osimertinib vs
in lung cancer (metastatic)
10/08/2016 00:00:00

EGFR inhibitors for lung cancer (metastatic) in all type of patients

IRIS, 2016
NCT00091949
pioglitazone vs placebo
in diabetes type 2
02/05/2016 00:00:00

glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients

SWITCH,
NCT00732914
sunitinib vs sorafenib
in advanced renal-cell carcinoma
07/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in first line

multi target TKI for advanced renal-cell carcinoma in all type of patients

RECORD 3, 2014
NCT00903175
everolimus vs sunitinib
in advanced renal-cell carcinoma
07/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in first line

mTOR inhibitor for advanced renal-cell carcinoma in all type of patients

Powles, 2014apitolisib vs everolimus
in advanced renal-cell carcinoma
07/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in first line

multi target TKI for advanced renal-cell carcinoma in all type of patients

VEG105192, 2010
NCT00334282
pazopanib vs placebo
in advanced renal-cell carcinoma
07/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in 2nd line treatment

multi target TKI for advanced renal-cell carcinoma in all type of patients

GOLD,
NCT01223027
dovitinib vs sorafenib
in advanced renal-cell carcinoma
07/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in 2nd line treatment

multi target TKI for advanced renal-cell carcinoma in all type of patients

Disruptor-1, BNC105P + everolimus vs everolimus
in advanced renal-cell carcinoma
07/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in first line

multi target TKI for advanced renal-cell carcinoma in all type of patients

INTORSECT, 2014
NCT00474786
temsirolimus vs sorafenib
in advanced renal-cell carcinoma
07/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in 2nd line treatment

mTOR inhibitor for advanced renal-cell carcinoma in all type of patients

Qin, 2012axitinib vs sorafenib
in advanced renal-cell carcinoma
07/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in first line

multi target TKI for advanced renal-cell carcinoma in all type of patients

Motzer, 2007
NCT00083889
sunitinib vs interferon alpha
in advanced renal-cell carcinoma
05/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in first line

multi target TKI for advanced renal-cell carcinoma in all type of patients

Escudier, 2009sorafenib vs interferon alpha
in advanced renal-cell carcinoma
05/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in first line

multi target TKI for advanced renal-cell carcinoma in all type of patients

ARCC (Hudes) temsirolimus alone, 2007
NCT00065468
temsirolimus vs interferon alpha
in advanced renal-cell carcinoma
05/12/2015 00:00:00

All mechanism for advanced renal-cell carcinoma in first line

mTOR inhibitor for advanced renal-cell carcinoma in all type of patients

OlympiAD, 2017
NCT02000622
olaparib vs Physician s choice chemotherapy
in advanced breast cancer (metastatic)
31/10/2015 00:00:00

poly ADP-ribose polymerase (PARP) inhibitor for advanced breast cancer (metastatic) in HER 2 negative

poly ADP-ribose polymerase (PARP) inhibitor for advanced breast cancer (metastatic) in all type of patients

poly ADP-ribose polymerase (PARP) inhibitor for advanced breast cancer (metastatic) in BRCA-mutated

LEADERS FREE,
NCT01623180
vs
in percutaneous coronary intervention
14/10/2015 00:00:00

bioresorbable vascular scaffold for percutaneous coronary intervention in all type of patients

ABSORB II,
NCT01425281
(Absorb, Abbott Vascular, vs everolimus-eluting metallic stent
in percutaneous coronary intervention
14/10/2015 00:00:00

bioresorbable vascular scaffold for percutaneous coronary intervention in all type of patients

AVOID HF,
NCT01474200
ultrafiltration vs
in acute heart failure
13/10/2015 00:00:00

new drug under development for acute heart failure in all type of patients

ultrafiltration for acute heart failure in all type of patients